|
1）Gianluca A, Luigi C, Laura del S. Multidrug therapy for polycystic kidney disease: A review and perspective. Am J Nephrol. 2013; 37: 175-82
|
|
|
|
2）Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367: 2407-18
|
|
|
|
|
|
3）Hildebrant F, Benzing T, Katsanis N. Ciliopathies. N Engl J Med. 2011; 364: 1533-43
|
|
|
|
|
|
4）Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal dominant polycystic kidneys. Kidney Int. 2003; 63: 1983-94
|
|
|
|
|
|
5）Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease : contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001; 38: 777-84
|
|
|
|
|
|
6）Rahman E, Niaz FA, Al-Suwaida A, et al. Analysis of cause of mortality in patients with autosomal dominant polycystic kidney disease-a single center study. Saudi J Kidney Dis Transpl. 2009; 20: 806-10
|
|
|
|
|
|
7）Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003; 9: 1323-6
|
|
|
|
|
|
8）Masyuk TV, Masyuk AI, Torres VE, et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3’, 5’-cyclic monophosphate. Gastroenterology. 2007; 132: 1104-16
|
|
|
|
|
|
9）Hogan MC, Masyuk TV, Page LJ, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol. 2010; 21: 1052-61
|
|
|
|
|
|
10）Hogan MC, Masyuk TV, Page LJ, et al. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant. 2012; 27: 3532-9
|
|
|
|
|
|
11）Distefano G, Boca M, Rowe I, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K1 and 4EBP1. Mol Cell Biol. 2009; 29: 2359-71
|
|
|
|
|
|
12）Dere R, Wilson PD, Sandford RN, et al. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One. 2010; 5: e9239
|
|
|
|
|
|
13）Hsu PP, Kang SA, Rameseder J,et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011; 332: 1317-22
|
|
|
|
|
|
14）Yu Y, Yoon SO, Poulogiannis G, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Sience. 2011; 332: 1322-6
|
|
|
|
|
|
15）Shilingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A. 2006; 103: 5466-71
|
|
|
|
|
|
16）Serra AL, Poster D, Kistler AD, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 820-9
|
|
|
|
|
|
17）Novalic Z, van der Wal AM, Leonhard WN, et al. Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol. 2012; 23: 842-53
|
|
|
|
|
|
18）Walz G, Budde K, Mannaa M, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2010; 363: 830-40
|
|
|
|
|
|
19）Torres VE, Sweeney WE Jr, Wang X, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han: SPRD rats. Kidney Int. 2003; 64: 1573-9
|
|
|
|
|
|
20）Yamaguchi T, Pelling JC, Ramaswamy NT, et al. cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathway. Kidney Int. 2000; 57: 1460-71
|
|
|
|
|
|
21）Shibazaki S, Yu Z, Nishio S, et al. Cyst formation and activation of the extracellular regulated kinase pathway after kidney-specific inactivation of Pkd1. Hum Mol Genet. 2008; 17: 1505-16
|
|
|
|
|
|
22）Omori S, Hida M, Fujita H, et al. Extracellular signal-regulated kinase inhibition slows disease progression in mice with polycystic kidney disease. J Am Soc Nephrol. 2006; 17: 1604-14
|
|
|
|
|
|
23）Gao J, Zhou H, Lei T, et al. Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol. 2011; 654: 92-9
|
|
|
|
|
|
24）Leonhard WN, van der Wal A, Novalic Z, et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol. 2011; 300: F1193-202
|
|
|
|
|
|
25）Elliott J, Zheleznova NN, Wilson PD. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am J Physiol Cell Physiol. 2011; 301: C522-9
|
|
|
|
|
|
26）Leuenroth SJ, Okuhara D, Shotwell JD, et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A. 2007; 104: 4389-94
|
|
|
|
|
|
27）Leuenroth SJ, Bencivenga N, Igarashi P, et al. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol. 2008; 19: 1659-62
|
|
|
|
|
|
28）Takiar V, NishioS, Seo-Mayer P, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A. 2011; 108: 2462-7
|
|
|
|
|